{"entity":{"id":"nct05393635","kind":"trial","name":"ITIL-168 in Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of ITIL-168 run by Instil Bio, withdrawn before enrolling.","summary":"ITIL-168 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT05393635 by Instil Bio, started 2022-08. Conditions recorded: Cervical Cancer, Head and Neck Squamous Cell Carcinoma and Non-small Cell Lung Cancer. Interventions recorded: ITIL-168.","status":"withdrawn","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05393635","url":"https://clinicaltrials.gov/study/NCT05393635"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cervical","head-and-neck","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["itil-168"],"companies":["instil-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05393635","phase":"1","setting":"A Phase 1, Open-Label, Multicenter Study Evaluating the Safety, Feasibility, and Preliminary Efficacy of ITIL-168 With Pembrolizumab in Subjects With Advanced Solid Tumors","sponsor":"Instil Bio","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05393635/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"itil-168","kind":"drug","name":"ITIL-168","route":"/drugs/itil-168/"}],"company":[{"id":"instil-bio","kind":"company","name":"Instil Bio","route":"/companies/instil-bio/"}]}}